Pharmabiz1h
Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma
Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...
Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...
FiercePharma12h
Ahead of adcomm, FDA challenges broad use of PD-1 drugs in stomach cancer patients
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
Pharmabiz6d
Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM
Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM: Rahway, New Jersey Thursday, September 19, 2024, ...
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society ...
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...